Correlation Between Kymera Therapeutics and Lyell Immunopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Kymera Therapeutics and Lyell Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kymera Therapeutics and Lyell Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kymera Therapeutics and Lyell Immunopharma, you can compare the effects of market volatilities on Kymera Therapeutics and Lyell Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kymera Therapeutics with a short position of Lyell Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kymera Therapeutics and Lyell Immunopharma.

Diversification Opportunities for Kymera Therapeutics and Lyell Immunopharma

0.42
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Kymera and Lyell is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Kymera Therapeutics and Lyell Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyell Immunopharma and Kymera Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kymera Therapeutics are associated (or correlated) with Lyell Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyell Immunopharma has no effect on the direction of Kymera Therapeutics i.e., Kymera Therapeutics and Lyell Immunopharma go up and down completely randomly.

Pair Corralation between Kymera Therapeutics and Lyell Immunopharma

Given the investment horizon of 90 days Kymera Therapeutics is expected to generate 0.67 times more return on investment than Lyell Immunopharma. However, Kymera Therapeutics is 1.5 times less risky than Lyell Immunopharma. It trades about 0.06 of its potential returns per unit of risk. Lyell Immunopharma is currently generating about -0.02 per unit of risk. If you would invest  2,338  in Kymera Therapeutics on August 31, 2024 and sell it today you would earn a total of  2,347  from holding Kymera Therapeutics or generate 100.38% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Kymera Therapeutics  vs.  Lyell Immunopharma

 Performance 
       Timeline  
Kymera Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Kymera Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable primary indicators, Kymera Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.
Lyell Immunopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Kymera Therapeutics and Lyell Immunopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Kymera Therapeutics and Lyell Immunopharma

The main advantage of trading using opposite Kymera Therapeutics and Lyell Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kymera Therapeutics position performs unexpectedly, Lyell Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will offset losses from the drop in Lyell Immunopharma's long position.
The idea behind Kymera Therapeutics and Lyell Immunopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Complementary Tools

Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum